Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lowenstein

Showing results (401-410 of 436) with videos related to

Pageof 44
Sort By:
Practical Radiation Oncology|June 28, 2016
Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastasesHania A Al-Hallaq, Steven Chmura, Joseph K Salama, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
MIF-mediated reprogramming of myeloid lineage within the glioma tumor microenvironment impacts the efficacy of immune stimulatory gene therapyZiwen Zhu, Noah C Kanis, Anthony E George, et al.
Expert Opinion on Biological Therapy|January 22, 2020
Prospects of biological and synthetic pharmacotherapies for glioblastomaDavid B Altshuler, Padma Kadiyala, Felipe J Nuñez, et al.
Journal of Virology|December 17, 2008
Herpes simplex virus type 1 thymidine kinase sequence fused to the lacz gene increases levels of {beta}-galactosidase activity per genome of high-capacity but not first-generation adenoviral vectors in vitro and in vivoM Puntel, R J Barrett, S Mondkar, et al.
Oncotarget|September 2, 2016
Characterizing and targeting PDGFRA alterations in pediatric high-grade gliomaCarl Koschmann, Daniel Zamler, Alan MacKay, et al.
Plos Medicine|January 16, 2009
HMGB1 mediates endogenous TLR2 activation and brain tumor regressionJames F Curtin, Naiyou Liu, Marianela Candolfi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2009
Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicityMarianela Candolfi, Kader Yagiz, David Foulad, et al.
Frontiers in Oncology|June 25, 2021
Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated TherapiesMaria B Garcia-Fabiani, Santiago Haase, Andrea Comba, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2010
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeuticsMarianela Candolfi, Weidong Xiong, Kader Yagiz, et al.
Toxicology and Applied Pharmacology|February 14, 2013
Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastomaMariana Puntel, Ghulam Muhammad A K M, Catherine Farrokhi, et al.
Pageof 44

Showing results (401-410 of 436) with videos related to

Sort By:
Pageof 44
Practical Radiation Oncology|June 28, 2016
Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastasesHania A Al-Hallaq, Steven Chmura, Joseph K Salama, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
MIF-mediated reprogramming of myeloid lineage within the glioma tumor microenvironment impacts the efficacy of immune stimulatory gene therapyZiwen Zhu, Noah C Kanis, Anthony E George, et al.
Expert Opinion on Biological Therapy|January 22, 2020
Prospects of biological and synthetic pharmacotherapies for glioblastomaDavid B Altshuler, Padma Kadiyala, Felipe J Nuñez, et al.
Journal of Virology|December 17, 2008
Herpes simplex virus type 1 thymidine kinase sequence fused to the lacz gene increases levels of {beta}-galactosidase activity per genome of high-capacity but not first-generation adenoviral vectors in vitro and in vivoM Puntel, R J Barrett, S Mondkar, et al.
Oncotarget|September 2, 2016
Characterizing and targeting PDGFRA alterations in pediatric high-grade gliomaCarl Koschmann, Daniel Zamler, Alan MacKay, et al.
Plos Medicine|January 16, 2009
HMGB1 mediates endogenous TLR2 activation and brain tumor regressionJames F Curtin, Naiyou Liu, Marianela Candolfi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2009
Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicityMarianela Candolfi, Kader Yagiz, David Foulad, et al.
Frontiers in Oncology|June 25, 2021
Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated TherapiesMaria B Garcia-Fabiani, Santiago Haase, Andrea Comba, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2010
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeuticsMarianela Candolfi, Weidong Xiong, Kader Yagiz, et al.
Toxicology and Applied Pharmacology|February 14, 2013
Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastomaMariana Puntel, Ghulam Muhammad A K M, Catherine Farrokhi, et al.
Pageof 44